Stanley Druckenmiller doesn’t do consensus. The Duquesne Family Office’s latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline. Miss this map and you’re paying retail for what he already owns.
1. BBB Foods (TBBB): The Mexican Discounter Nobody’s Talking About
The surprise anchor of the portfolio is BBB Foods (NYSE:TBBB), a $4.84 billion hard-discount grocer running the Tiendas 3B banner across Mexico. This is a countercyclical bet dressed up as a growth story: the weaker the Mexican consumer gets, the faster private-label discount stores capture wallet share. Druckenmiller is buying the pain trade.
The Q1 2026 numbers explain the conviction. Revenue grew 33.44% year-over-year to roughly Ps.22.86 billion, same-store sales advanced 16.0%, and the store base expanded to 3,469 units after 123 net openings in the quarter. CEO K. Anthony Hatoum framed it plainly: “Despite a soft consumer environment in Mexico, we achieved same-store sales (SSS) growth of 16.0% in 1Q26, underscoring the strength of our value proposition and increasing customer loyalty.”
The model puts a base-case one-year target of $50.82, or 26.89% upside, with analysts split 75% bullish and zero bearish. The setup skews constructive. And the second name on Druckenmiller’s list is a very different kind of asymmetric bet, where the launch curve is already vertical.
2. Insmed (INSM): The BRINSUPRI Breakout
Insmed (NASDAQ:INSM | INSM Price Prediction) is a rare-disease pharma whose newly launched bronchiectasis drug BRINSUPRI has turned into one of the fastest specialty-drug ramps of the decade. Druckenmiller is positioned for what happens when a first-in-class therapy meets a captive prescriber base with essentially no competition.
Q1 2026 revenue hit $305.96 million, up 229.6% year-over-year, with BRINSUPRI alone contributing $207.90 million in its first full quarter, growing 44% sequentially. Management reaffirmed full-year 2026 guidance of at least $1.0 billion for BRINSUPRI and $1.45 billion total, implying roughly 139% growth. CEO Will Lewis told investors, “The trajectory of the BRINSUPRI launch continues to exceed our expectations.”
Here’s the setup: shares are down 38.26% year-to-date even as the fundamentals accelerate. The AI model’s base case sees $226.62 in twelve months, or 108.48% upside, with analysts 100% bullish across 22 ratings and zero holds. The setup skews aggressively constructive for investors willing to stomach volatility. The next name is the exact opposite profile: the one stock Druckenmiller owns that every fund manager on the planet already knows they should own too.
3. Taiwan Semiconductor (TSM): The AI Foundry Monopoly
Taiwan Semiconductor Manufacturing (NYSE:TSM) is the obvious heavyweight, and Druckenmiller owns it anyway because you can’t build an AI portfolio without the company that fabricates the chips. NVIDIA, AMD, and every hyperscaler custom silicon program feed through TSMC’s advanced nodes. The moat is the only road.
Q2 2026 EPS came in at $4.31 versus a $3.89 consensus, a 10.89% beat, on revenue of $40.20 billion, up 36.0% year-over-year. Gross margin expanded to 67.7%. Management guided full-year 2026 revenue growth to “slightly above 40%” in U.S. dollar terms, with 2nm technology debuting at 3% of wafer revenue in its first commercial quarter.
Polymarket traders priced the Q1 2026 earnings beat at 0.999 probability, essentially certainty, and the crowd nailed both Q2 revenue and gross margin resolutions with an average accuracy score of 0.869. Analyst consensus target sits at $498.24 against 89% bullish sentiment. The setup remains constructive. And when a manager like Druckenmiller pairs the world’s most important foundry with a diagnostic company processing a million tests a quarter, the through-line becomes clear.
4. Natera (NTRA): The Million-Tests-a-Quarter Milestone
Natera (NASDAQ:NTRA) is the precision-medicine leg of the book, dominant in oncology minimal residual disease testing through Signatera and in prenatal screening through Panorama and Fetal Focus. This is the volume-flywheel thesis: more tests processed means more clinical data, more payor coverage, more prescribers, more tests.
Q1 2026 revenue reached $696.64 million, up 38.8% year-over-year and beating consensus by 12.90%. The company crossed 1,013,600 tests processed in a single quarter for the first time, with oncology volumes up 54.4% year-over-year. Management raised full-year 2026 revenue guidance to $2.74 billion to $2.82 billion, a $120 million increase at the midpoint. CEO Steve Chapman called it “an outstanding first quarter, reaching over one million units processed in a single quarter for the first time.”
Shares are up 17.78% year-to-date and 81.83% over the past twelve months. Base-case model target is $322.28, or 19.32% upside, with analyst sentiment 86% bullish and zero bearish. The setup skews constructive, with the caveat that ongoing losses require patience. Which sets up the final slot, and the position with arguably the sharpest 2027 catalyst on the entire list.
5. YPF (YPF): The Vaca Muerta Payoff
YPF Sociedad Anonima (NYSE:YPF) is Druckenmiller’s emerging-markets energy call, and it lands as the #5 payoff because a specific date sits inside the thesis: January 2027, when the VMOS export pipeline turns on. This is Argentina’s shale story written as a hard catalyst.
Q1 2026 EPS came in at $1.03 versus a $0.88 consensus, a 17.05% beat, swinging the company to $409 million in net profit from a $649 million loss the prior quarter. Shale oil production reached 205 kbbl/d, up 39% year-over-year and now 76% of total oil output. The VMOS export pipeline is roughly 62% complete with first oil export targeted for January 2027, and lifting costs fell 42% year-over-year.
Shares are up 33.99% year-to-date and 57.25% over the past twelve months. The model base case targets $61.94, or 25.75% upside, with analyst sentiment 77% bullish and zero bearish. Argentina’s 51% government stake is the risk you accept for the reward. The setup skews constructive with position sizing discipline.
The Through-Line
Druckenmiller’s top five is a barbell: two US-listed AI and precision-medicine engines (TSM, NTRA), one specialty-pharma launch curve (INSM), and two emerging-markets asymmetric bets (TBBB, YPF) where the macro pain is the entry point. Every name carries a bullish analyst majority and a base-case upside north of 19%. The VMOS pipeline turns on in January 2027. BRINSUPRI’s next earnings report lands before year-end. The window to buy alongside the trade is narrowing fast.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks